Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31045879 | 0.89 | MTNR1A (0.45) | MTNR1AMTNR1BHTTKDM4EALDH1A1 | |
| SCHEMBL31045663 | 0.84 | MTNR1A (0.47) | MTNR1AMTNR1BHTTKDM4EALDH1A1 | |
| SCHEMBL9926555 | 0.83 | MEP1B (0.41) | HTTKDM4EALDH1A1L3MBTL1MEP1B | |
| SCHEMBL9926582 | 0.80 | IDO1 (0.38) | HTTKDM4EALDH1A1L3MBTL1P2RX7 | |
| SCHEMBL31045837 | 0.79 | MTNR1A (0.44) | MTNR1AMTNR1BHTTKDM4EALDH1A1 | |
| SCHEMBL9926557 | 0.79 | CXCL8 (0.41) | SMN1; SMN2 | |
| SCHEMBL9926581 | 0.79 | CA1 (0.48) | HTTKDM4EALDH1A1P2RX7 | |
| SCHEMBL9926662 | 0.78 | ICMT (0.38) | HTTP2RX7 | |
| SCHEMBL9926670 | 0.77 | PIK3CD (0.40) | HTTKDM4EALDH1A1P2RX7 | |
| SCHEMBL31062319 | 0.77 | SSTR4 (0.42) | MTNR1AMTNR1BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MTNR1A 214/4885MTNR1B 443/4885HTT 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.